Inhibrx enrolls its first patient of Phase 1 trial of INBRX-101
Category: #health  By Mateen Dalal  Date: 2019-09-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Inhibrx enrolls its first patient of Phase 1 trial of INBRX-101
  • INBRX-101 is built to provide greater clinical activity to pdAAT by offering sustained improved concentration of plasma within a less frequent, regimen of monthly dosing.  
     
  • Inhibrx anticipates to unveil preliminary functional pharmacokinetic data collected during the single-dose phase of the study in the first six months of 2020.

Inhibrx Inc., an international biotechnology company founded in 2010 aimed at developing a pipeline of new biologic therapeutic candidates, reportedly announced the registration of first patient in its Phase 1 clinical trial of a therapeutic candidate INBRX-101 (NCT03815396).

NCT03815396 is a therapeutic candidate based on Fc-fusion protein which comprises improved recombinant iterations of human alpha-1 antitrypsin to treat alpha-1 antitrypsin deficiency, commonly called AATD, in patients.

AATD is a rare respiratory disease that is characterized by continuous impairment of lung tissue which leads to emphysema and COPD. Reports cite, approx. 100,000 people are affected by this disease across the United States with Europe numbers being at the same approximate level.

Plasma derived augmentation therapy (pdAAT), present standard of care of patients affected with AATD, has remained unchanged for several decades and depends on the weekly infusions of AAT derived from plasma purified from the human donor serum.

The company’s therapeutic candidate INBRX-101 is developed to provide greater clinical activity into pdAAT by offering sustained improved concentration of plasma within a less frequent, regimen of monthly dosing.   

CEO of Inhibrx, Mark Lappe stated that the company applied its protein engineering capabilities for overcoming the challenges associated with producing functional recombinant human alpha-1 antitrypsin, apart from identifying modifications that the company believes to be capable to optimize PK functionality and profile. Mark further added that the company is thrilled to start enrollment of Phase 1 trial to assess the potential advantages of INBRX-101 in individuals affected by AATD.

Inhibrx anticipates to unveil preliminary functional pharmacokinetic data collected during the single-dose phase of the study in the first 6 months of 2020.

 

Source credit: https://inhibrx.com/inhibrx-announces-enrollment-of-first-patient-in-phase-1-study-of-inbrx-101-a-modified-recombinant-human-aat-fc-fusion-protein/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Knopp posts data of KB-3061 working on KCNQ2 Epileptic Encephalopathy
Knopp posts data of KB-3061 working on KCNQ2 Epileptic Encephalopathy
By Mateen Dalal

KCNQ2 epileptic encephalopathies is a serious type of neonatal epileptic condition which manifests in newborn children during the first week if their lives. This disease is being addressed by various pharmaceutical companies across the globe trying t...

Novo Nordisk and Medtronic team up to offer digital diabetes solutions
Novo Nordisk and Medtronic team up to offer digital diabetes solutions
By Mateen Dalal

With growing population of diabetic patients, diabetes management is becoming a daunting activity. Sugar level management and insulin injections tracking is a difficult work. Thus, leading pharmaceutical companies are collaborating with medical devic...

Akesis unveils its advanced Galaxy™ RTi and Gemini360 at ASTRO 2019
Akesis unveils its advanced Galaxy™ RTi and Gemini360 at ASTRO 2019
By Mateen Dalal

The healthcare company will showcase its drugs in the ASTRO annual meeting 2019 that could help offer improved efficiency and confidence in treatment delivery. Akesis, Inc., a hospital and healthcare company based in the U.S. that offers innovative...